Company intelligence / Profile preview

Quincy Bioscience

Middleton, Wisconsin, United Statesquincybioscience.com ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

A landmark double-blind and placebo-controlled trial was conducted, but the scientific validity of their claims has been challenged. In 2024, a federal court ordered the company to cease making memory improvement claims after a jury found they made fraudulent and deceptive statements about Prevagen[6][9].

Therapeutic areas: Neurology
Modalities: Dietary supplements containing apoaequorin
Industry: Food & Nutrition

Drug pipeline

1 asset

Prevagen

Commercial

Indications: Cognitive impairment, Memory loss

Beyond the preview

Go deeper on Quincy Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quincy Bioscience.

Explore the full profile